Q3 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Novartis pipeline in Phase 2 Oncology Conclusions Appendix Innovation: Clinical trials Immunology References Abbreviations INNOVATION 21 lead indications Code Name Mechanism Indication(s) Solid tumors AAA601 BCR-ABL inhibitor JDQ443 opnurasib TNO155 TNO155 Hematology ABL001 ScemblixⓇ INC424 Jakavi® MBG453 sabatolimab PHE885 durcabtagene autoleucel PKC412 Rydapte YTB323 rapcabtagene autoleucel JAK1/2 inhibitor TIM3 antagonist BCMA cell therapy Multi-targeted kinase inhibitor CD19 CAR-T Acute myeloid leukemia, pediatrics 1L high-risk large B-cell lymphoma LutatheraⓇ Radioligand therapy target SSTR GEPNET, pediatrics 1L ES-SCLC Glioblastoma LNA043 LNA043 KRAS inhibitor SHP2 inhibitor NSCLC and CRC (mono and/or combo) Solid tumors LOU064 remibrutinib BTK inhibitor Code CFZ533 Name iscalimab Mechanism CD40 inhibitor DFV890 DFV890 NLRP3 inhibitor Indication(s) Chronic myeloid leukemia, 2L, pediatrics Acute GVHD, pediatrics Chronic GVHD, pediatrics Unfit acute myeloid leukemia LRX712 LRX712 MAS825 MAS825 MHV370 MHV370 Acute myeloid leukemia, maintenance 4L multiple myeloma NG1226 NG1226 QUC398 QUC398 RHH646 RHH646 ANGPTL3 agonist TLR7, TLR8 Antagonist ADAMTS5 inhibitor Sjögren's Hidradenitis suppurativa Knee osteoarthritis Familial cold auto-inflammatory syndrome Knee osteoarthritis Osteoarthritis (combos) Food allergy Hidradenitis suppurativa Sjögren's Osteoarthritis NLRC4-GOF indications Sjögren's Mixed connective tissue disease Tendinopathy Osteoarthritis Osteoarthritis VAY736 ianalumab YTB323 rapcabtagene autoleucel BAFF-R inhibitor CD19 CAR-T Autoimmune hepatitis srSLE/LN Neuroscience Code Name BLZ945 sotuletinib DLX3131 minzasolmin Mechanism CSF-1R inhibitor Alpha-synuclein misfolding inhibitor Indication(s) Others Amyotrophic lateral sclerosis Parkinson's disease Code IB&GH Name KAE609 cipargamin KLU156 Indication(s) Ganaplacide + lumefantrine Cardiovascular Code Name CFZ533 iscalimab LNP023 iptacopan TIN816 TIN816 XXB750 Mechanism CD40 inhibitor Lupus nephritis CFB inhibitor Lupus nephritis ATP modulator XXB750 NPR1 agonist Acute kidney injury Hypertension 1. DLX313 is the Novartis compound code for UCB0599. 35 Investor Relations | Q3 2023 Results LXE408 LXE408 QMF149 Atectura® SEG101 Adakveo® Others Mechanism Indication(s) PfATP4 inhibitor Non-artemisinin plasmodium falciparum inhibitor Proteasome inhibitor LABA + ICS P-selectin inhibitor Malaria, severe Malaria, uncomplicated Malaria, uncomplicated Visceral leishmaniasis Asthma, pediatrics Sickle cell disease, pediatrics CMK389 CMK389 LNP023 LTP001 IL-18 inhibitor iptacopan LTP001 CFB inhibitor SMURF1 inhibitor Pulmonary sarcoidosis iAMD Pulmonary arterial hypertension Idiopathic pulmonary fibrosis Lead indication U NOVARTIS | Reimagining Medicine

View entire presentation